About This Test
This assay is useful in evaluating patients with Celiac disease including those with compatible symptoms, atypical symptoms and individuals at increased risk such as those positive for HLA DA2/DQ8. Ingestion of Gliadin peptides contained in wheat, rye and barley induce immune mediated inflammation of small intestine in genetically susceptible individuals with Gluten sensitive enteropathy / Celiac disease. This disease is more common in first and second degree relatives of patients with Celiac disease, individuals with Down Syndrome, Turner syndrome, Williams syndrome, Selective IgA deficiency and Autoimmune disorders. Usage of Deamidated molecule increases the specificity and sensitivity of the assay. It is also used as a screeing test for Dermatitis herpetiformis. This assay also monitors adherence to gluten free diet. Test sensitivity increases from 91.5% for tTG IgA antibody alone to 98.5 % when both IgA and IgG antibodies are tested together.
Test Parameters (1)
- tTg DGP COMBINED SCREEN PANEL
Home Collection
✓ Available
Reports Available In
2 Days
Frequently Asked Questions
Outsourced test are being done from Dr. Lal Path Lab. Charges and reporting time is same as of Dr. Lal Path Labs.
No special preparation required
The tTG–DGP Combined Screen Panel is important because it improves the accuracy of celiac disease screening, enabling early diagnosis, especially in patients where a single test may be falsely negative.
TAT Policy
The Turnaround Time (TAT) depends on the following factors:
- Registration date and time
- Type of scan or test
- Scan time or sample collection time
In uncommon circumstances, TAT may be delayed due to test complexity or reasons beyond our control. You will be informed of the estimated TAT at the time of registration.
